NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) said the European Commission has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of COVID-19 vaccine candidate to EU member states following approval. The member states also have the option to secure up to 200 million additional doses.
Johnson & Johnson has also announced plans to allocate up to 500 million vaccine doses toward international efforts to ensure access for lower income countries, with delivery beginning mid next year.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de